Institute for Precision Cardiovascular Medicine
The AHA Institute for Precision Cardiovascular Medicine created a new model for bringing together science and technology to drive breakthroughs in cardiovascular and brain health and disease.
The American Heart Association (AHA) Institute for Precision Cardiovascular Medicine (Institute) is at the forefront of the application of data science and technology to the fields of cardiovascular and brain disease and well-being.
We're working with experts, empowering individuals, more fully equipping researchers, training problem solvers, fueling and funding scientific discoveries, and translating science for clinicians and patients.
Since 2014, we've funded more than 80 grants totaling more than $30.5 million.
The AHA Precision Medicine Platform offers cloud-computing, diverse datasets, data harmonization, and secure workspaces equipped with state of the art analytics tools, such as artificial intelligence, to researchers around the globe.
The American Heart Association's Go Red for Women® movement and Verily's Project Baseline have joined forces to launch Research Goes Red, an initiative calling on women across the United States to contribute to health research.
Through a $75 million investment in a diverse team of scientists, One Brave Idea has set out to find the weapons and strategies to win the fight against coronary heart disease.
Grantees have published more than 200 papers in scientific journals.
The Center for Accelerated Drug Discovery is leveraging the power of supercomputing to reduce the time to market for new drugs and therapies by up to 50 percent.
Advancing the science of precision medicine together. Meet our strategic collaborators.
Zechen Chong, Ph.D."I noticed that because of limitations in technology, many unresolved problems in genomics were actually computational problems. So, I decided to take advantage of my computational skills and apply them to the genomics field to solve these problems in order to improve the overall health of the human being."
Brian P. Delisle, Ph.D.“Part of precision medicine is not only looking at genetic variants, but also taken into account the gene and environment interactions that may also contribute to the risk for this disease.”
Stacey Knight, Ph.D.“Our project takes those two very large datasets and uses the AHA Precision Medicine Platform to accelerate findings of cardiovascular disease-related genetic causes”
Juan Zhao, Ph.D.
“Looking beyond conventional factors is essential for accurate stroke prevention, especially given that stroke is preventable, and its first sign may be fatal"